Orchid Pharma Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma reported audited standalone profit before tax of Rs. 4,520.79 lakhs for FY2025-26, a significant decline from Rs. 10,648.34 lakhs in the previous year. Standalone total income fell to Rs. 86,656.92 lakhs from Rs. 95,385.50 lakhs. The statutory auditors issued an unmodified opinion on standalone results but a qualified opinion on consolidated results due to unaudited financials of 3 US subsidiaries. The company completed acquisition of 100% global rights to Enmetazobactam (EXBLIFEP) through Allecra Therapeutics in Germany and France, and also acquired Orchid Pharma Europe GmbH. The proposed amalgamation of parent Dhanuka Laboratories Limited is awaiting NCLT approval. Cash and cash equivalents declined to Rs. 123.96 lakhs from Rs. 1,587.08 lakhs, while capital work-in-progress increased significantly to Rs. 34,052.11 lakhs on consolidated basis indicating heavy investment in new facilities.
The steep decline in annual profit (down ~58% YoY on standalone) may concern short-term investors despite positive operational developments. The qualified audit opinion on consolidated results adds caution. However, the strategic acquisitions of Enmetazobactam and ongoing capacity expansion (Jammu facility, new API block) could drive future growth.